logo
Morningstar says Korean stocks are emerging markets' best bet for decade

Morningstar says Korean stocks are emerging markets' best bet for decade

Korea Herald10-07-2025
A fund manager at Morningstar Wealth is selling Chinese and Japanese equities to increase exposure to South Korea, which he's betting on to provide the best returns in both emerging and Asian markets over the next decade.
Korea's key draws are technology stocks tied to the artificial intelligence boom and a newfound political will for corporate reforms, according to Mark Preskett, a London-based senior portfolio manager at the firm. He said he's betting on annual returns from Korean stocks of 11 percent-12 percent in dollar terms over the next 10 years.
Preskett is unfazed by US President Donald Trump's announcement Monday of a 25 percent tariff on Korean imports, saying that his base case is for 'some kind of agreement to be signed by the two countries in the coming weeks.' He said that the lack of any escalation on existing tariffs on autos, and the exemption of electronics and pharmaceuticals, were also positives for his outlook on Korea.
The benchmark Kospi index has climbed more than 30 percent this year, making it one of the world's top performers in 2025. Global funds poured about $3 billion into Korean equities in May and June around the election of President Lee Jae Myung, who has intensified efforts to improve corporate governance standards and raise equity valuations.
'Korea stands out at the top in terms of expected returns,' Preskett said in an interview in London. 'We see this as the beginning of a revaluation story.'
The fund manager said he's encouraged by the government's drive to codify corporate governance reform with its 'Value-Up' program, while legal changes approved by parliament last week will help alleviate longstanding concerns about minority shareholder rights and the dominance of family-run chaebols.
The more stable government since Lee's election, along with concerted steps to reduce the 'Korea discount' of the nation's stocks versus emerging-market peers, are making the market more attractive, particularly relative to China, Preskett said. Companies in Korea have a weighting of less than 11 percent in the benchmark MSCI Emerging-Market Index, compared with China's 26 percent.
'We see Korea has some of the same attractiveness from a valuation perspective, but the fundamentals are a little stronger,' he said. 'You don't have this overhang of the property sector, you don't have the sort of question marks around shareholder governance.'
Among specific stocks, Preskett is positive on SK Hynix Inc. and Samsung Electronics Co. as makers of high-bandwidth memory chips that are crucial for AI. He also says they're undervalued, even with Samsung up by about 14 percent this year, and SK Hynix up 62 percent.
Corporate reforms
Risks remain for the market, even beyond tariffs, especially in terms of getting companies on board with the government's plans.
'Controlling shareholders may resist deeper reforms, particularly around capital management, and continue to suppress dividends under the guise of conservatism or future M&A,' said Jonathan Pines, head of Asia ex-Japan at Federated Hermes.
Recent market volatility is still fresh in investor's minds as well after the political turmoil around the previous president's declaration of martial law in December. With a further drag from Trump's tariffs, the Kospi slumped about 13% over two weeks into April.
Still, Preskett sees the Korea story as a strong long-term investment theme, noting that the new government has pledged fiscal reforms that should also help the consumer and banking sectors.
'For us, it is the start of a journey,' he said. 'We feel that it's tip of the iceberg in terms of flows and potential revaluation.' (Bloomberg)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

S. Korea, China FMs agree to make upcoming APEC summit 'new turning point' in ties
S. Korea, China FMs agree to make upcoming APEC summit 'new turning point' in ties

Korea Herald

time28 minutes ago

  • Korea Herald

S. Korea, China FMs agree to make upcoming APEC summit 'new turning point' in ties

The top diplomats of South Korea and China agreed Monday to work together to make the upcoming Asia-Pacific Economic Cooperation summit a "new turning point" in bilateral relations, as they held their first telephone call, the South Korean Foreign Ministry said. Foreign Minister Cho Hyun and Chinese Foreign Minister Wang Yi expressed this view during the 45-minute phone conversation, reaffirming their commitment to advance the bilateral strategic cooperative partnership in a "steady and mature" manner, the ministry said in a release. "They agreed to work together to ensure that the upcoming APEC summit in Gyeongju serves as a new turning point in bilateral ties and to deliver tangible outcomes in practical cooperation that can be felt by the peoples of both countries," it said. They also agreed to maintain the positive momentum in bilateral ties through high-level exchanges. The APEC summit is set to take place in the southeastern South Korean city from Oct. 31 to Nov. 1. Chinese President Xi Jinping is widely expected to attend the multilateral meeting. China is the host for next year's APEC summit. Congratulating Cho on his inauguration, Wang expressed a willingness to maintain a close working relationship with him, according to the ministry. Cho, in turn, said he hopes to closely work with Wang to further develop the Seoul-Beijing ties. Cho took office last Monday. He also extended an invitation for Wang to visit South Korea, and Wang responded that he would visit at a mutually convenient time, according to the ministry. (Yonhap)

FM to go on trip to Japan, US this week
FM to go on trip to Japan, US this week

Korea Herald

timean hour ago

  • Korea Herald

FM to go on trip to Japan, US this week

Foreign Minister Cho Hyun will visit Japan and the United States this week to meet his counterparts, according to the Ministry of Foreign Affairs on Monday. Cho, who took office on July 21, will meet his Japanese counterpart, Takeshi Iwaya, on Tuesday. Cho is scheduled to attend a working dinner hosted by Iwaya. It will be the first in-person meeting of the two since Cho started his term. The two held their first phone talks on Thursday and agreed that bilateral cooperation is key to addressing geopolitical challenges at both the global and regional levels. South Korea's top diplomat is scheduled to depart Tokyo for Washington on Wednesday to hold talks with Marco Rubio, who doubles as the US secretary of state and the national security adviser for the White House. Cho's meeting with Rubio is speculated to take place Thursday, but the Foreign Ministry did not disclose the exact date.

Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

Korea Herald

time2 hours ago

  • Korea Herald

Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the China National Medical Products Administration (NMPA) has approved XPOVIO ® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy, a new indication of XPOVIO ®. This approval for XPOVIO ® is based on the data of the BENCH trial, a randomized, controlled, open-label, multicenter Phase III bridging study which compared the safety and efficacy of XVd and Vd regimens in 154 Chinese patients with R/R MM who have received one to three prior lines of therapy. The efficacy and safety data of the BENCH study are generally consistent with those from the global, multicenter, Phase III BOSTON study and met the objectives of the bridging study which showed: Clear superiority of the XVd regimen: compared to the Vd regimen, the XVd regimen demonstrated better clinical efficacy, longer PFS and DOR, a higher ORR, a higher rate of very good partial response (VGPR) or deeper responses and minimal residual disease (MRD) negativity, as well as a trend of prolonged OS. Notable clinical benefits for elderly patients: the study observed particularly notable efficacy in the cohort of elderly patients aged ≥65, validating XPOVIO ® as a better treatment option for this patient population. Prof. Jin Lu, principal investigator of the BENCH study from Peking University People ' s Hospital, said, "MM is the second most common hematologic malignancy. The clinical application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in the first-line setting have resulted in longer overall survival for patients. However, the condition remains incurable with most patients end up relapsing. As a novel inhibitor of the nuclear export protein that adopts a novel mechanism of action, selinexor was proven by the BENCH study to be significantly efficacious in Chinese patients with MM. This approval for XPOVIO ® is a great news for patients with R/R MM, especially those relapsing for the first time." Prof. Jian Hou, principal investigator of the BENCH study from Shanghai Jiaotong University School of Medicine Affiliated Renji Hospital, commented, "The incidence of MM has been steadily rising year after year. According to the Globocan statistics for 2022, there were 30,300 new cases of MM and 18,662 MM related deaths in China, a figure that highlights an urgent unmet clinical need. Selinexor in combination with bortezomib and dexamethasone incorporates a unique mechanism of action and demonstrated significant efficacy. Moreover, XPOVIO ® does not require intravenous administration, therefore provides clinicians a new treatment strategy that can effectively reduce burden on patients." With a novel mechanism of action, XPOVIO ® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). While bringing XPOVIO ® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO ®. Leveraging the drug's novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO ® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO ® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store